Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis

Acute promyelocytic leukemia (APL) is a rare acute leukemia generally considered curable with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Some patients have co-morbidities that may limit the use of these agents and therefore impact curability. Adverse effects of ATO include life-threa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tinajero, Jose, El-Shami, Khaled, Wu, Xiaojun, Smith, B. Douglas, Newman, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968060/
https://www.ncbi.nlm.nih.gov/pubmed/35371914
http://dx.doi.org/10.1016/j.lrr.2022.100304
Descripción
Sumario:Acute promyelocytic leukemia (APL) is a rare acute leukemia generally considered curable with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Some patients have co-morbidities that may limit the use of these agents and therefore impact curability. Adverse effects of ATO include life-threatening electrocardiographic abnormalities. ATO and its metabolites are partially excreted in the urine, and it is unclear to what extent ATO pharmacokinetics are impacted by hemodialysis. We present a patient on chronic hemodialysis successfully treated with ATO and ATRA for newly diagnosed APL. Complete molecular remission was achieved after induction and several drug-related toxicities were managed.

Ejemplares similares